RNA 요법 시장 : 기술, 적응증, 최종 사용자별 - 세계 예측(2025-2030년)

The RNA Therapy Market was valued at USD 2.18 billion in 2023, expected to reach USD 2.60 billion in 2024, and is projected to grow at a CAGR of 22.38%, to USD 8.98 billion by 2030.

RNA therapy represents a cutting-edge segment of the biotechnology and pharmaceutical industries, focusing on the use of RNA molecules to treat a variety of diseases. This innovative approach includes RNA interference (RNAi), antisense oligonucleotides (ASOs), and messenger RNA (mRNA) therapies, which operate by targeting and manipulating genetic material. The necessity of RNA therapies is driven by their potential to treat conditions that are difficult to address with traditional small molecule and protein-based therapies, offering promise for genetic disorders, cancer, and rare diseases where precise genetic correction is crucial. The application and end-use scope of RNA therapy are expanding, with significant investments in drug discovery, clinical trials, and personalized medicine. Key growth factors include advancements in delivery technologies, increasing understanding of RNA mechanisms, and favorable regulatory frameworks. The latest potential opportunities in RNA therapy market innovation lie in refining delivery systems, expanding therapeutic targets, and developing cost-effective manufacturing processes. A focus on partnerships and collaborations with academic institutions and biotech companies could further accelerate innovation. However, challenges such as delivery efficacy, immunogenicity issues, and high development costs pose significant limitations, alongside regulatory hurdles and market competition. Areas ripe for innovation include nanoparticle-based delivery systems and the exploration of novel RNA modification techniques to enhance stability and minimize off-target effects. Given the rapid pace of advancements in genomics and biotechnology, the RNA therapy market is dynamic, characterized by a competitive landscape with a high degree of research and development activity. To capitalize on the evolving opportunities, stakeholders should emphasize interdisciplinary collaboration, integrate AI-driven drug discovery, and invest in scalable production technologies to enhance market penetration. Addressing these factors will be crucial for businesses aiming to capitalize on the promising future of RNA therapeutic advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving RNA Therapy Market

The RNA Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing understanding of the role of RNA in disease pathology
  • Heightened demand for personalized medicine
  • Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
• Market Restraints
  • High costs associated with RNA therapy development processes
• Market Opportunities
  • Increased investments by governments and private organizations in research and development activities
  • Pipelined clinical trials of RNA-based therapeutics
• Market Challenges
  • Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the RNA Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the RNA Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the RNA Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the RNA Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the RNA Therapy Market

A detailed market share analysis in the RNA Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the RNA Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the RNA Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Arbutus Biopharma Corporation, NeuBase Therapeutics, Inc., Moderna, Inc., Arcturus Therapeutics Holdings Inc., BioNTech SE, AstraZeneca PLC, Arrowhead Pharmaceuticals, Inc., Nordic Nanovector ASA, MiNA Therapeutics Limited, Silence Therapeutics PLC, Eli Lilly and Company, Cartesian Therapeutics, Inc., Novartis AG, Sirnaomics, Inc., F. Hoffmann-La Roche AG, ProQR Therapeutics N.V., Cenix BioScience GmbH, Nutcracker Therapeutics, Inc., Laronde, Triplet Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Deep Genomics, Biogen Inc., GSK PLC, Benitec Biopharma Limited, Sanofi S.A., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Enabled Technologies and Enabling Technologies. The Enabled Technologies is further studied across Inhibition, Labeling, Linear amplification, Microarrays, Purification, and qRT-PCR. The Enabling Technologies is further studied across RNA Antisense Technologies and RNA Interference Technologies. The RNA Antisense Technologies is further studied across MicroRNA and Small interfering RNA.
• Based on Indication, market is studied across Cancer, Cardiovascular, Genetic Disorders, Infectious Diseases, Kidney Diseases, Metabolic Disorders, Oncology, and Retinal Diseases.
• Based on End User, market is studied across Academic Research, Diagnostics, and Drug Discovery & Development.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing understanding of the role of RNA in disease pathology
    • 5.1.1.2. Heightened demand for personalized medicine
    • 5.1.1.3. Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with RNA therapy development processes
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased investments by governments and private organizations in research and development activities
    • 5.1.3.2. Pipelined clinical trials of RNA-based therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
  • 5.2.2. Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
  • 5.2.3. End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. RNA Therapy Market, by Technology

• 6.1. Introduction
• 6.2. Enabled Technologies
  • 6.2.1. Inhibition
  • 6.2.2. Labeling
  • 6.2.3. Linear amplification
  • 6.2.4. Microarrays
  • 6.2.5. Purification
  • 6.2.6. qRT-PCR
• 6.3. Enabling Technologies
  • 6.3.1. RNA Antisense Technologies
    • 6.3.1.1. MicroRNA
    • 6.3.1.2. Small interfering RNA
  • 6.3.2. RNA Interference Technologies

7. RNA Therapy Market, by Indication

• 7.1. Introduction
• 7.2. Cancer
• 7.3. Cardiovascular
• 7.4. Genetic Disorders
• 7.5. Infectious Diseases
• 7.6. Kidney Diseases
• 7.7. Metabolic Disorders
• 7.8. Oncology
• 7.9. Retinal Diseases

8. RNA Therapy Market, by End User

• 8.1. Introduction
• 8.2. Academic Research
• 8.3. Diagnostics
• 8.4. Drug Discovery & Development

9. Americas RNA Therapy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific RNA Therapy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa RNA Therapy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing
  • 12.3.2. ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million
  • 12.3.3. Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

Companies Mentioned

• 1. Arbutus Biopharma Corporation
• 2. NeuBase Therapeutics, Inc.
• 3. Moderna, Inc.
• 4. Arcturus Therapeutics Holdings Inc.
• 5. BioNTech SE
• 6. AstraZeneca PLC
• 7. Arrowhead Pharmaceuticals, Inc.
• 8. Nordic Nanovector ASA
• 9. MiNA Therapeutics Limited
• 10. Silence Therapeutics PLC
• 11. Eli Lilly and Company
• 12. Cartesian Therapeutics, Inc.
• 13. Novartis AG
• 14. Sirnaomics, Inc.
• 15. F. Hoffmann-La Roche AG
• 16. ProQR Therapeutics N.V.
• 17. Cenix BioScience GmbH
• 18. Nutcracker Therapeutics, Inc.
• 19. Laronde
• 20. Triplet Therapeutics, Inc.
• 21. Ionis Pharmaceuticals, Inc.
• 22. Alnylam Pharmaceuticals, Inc.
• 23. Deep Genomics
• 24. Biogen Inc.
• 25. GSK PLC
• 26. Benitec Biopharma Limited
• 27. Sanofi S.A.
• 28. Novo Nordisk A/S